G. Walmsley Graham, Director at Akero Therapeutics, Inc. (AKRO), bought 200,000 shares at $48.00 ($9.6M) on 2025-01-30, disclosed to the SEC on 2025-02-07.
Open-market purchase of $9.6M AKRO by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| OLMA | SELL | 2024-12-18 | $9.5M | — | Filing → |
| OLMA | BUY | 2024-12-17 | $4.7M | — | Filing → |
| OLMA | SELL | 2024-12-17 | $9.5M | — | Filing → |